Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*
Kenneth B. Gordon, Mark Lebwohl, Kim Papp, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 3, pp. 466-475
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis
James Yarmolinsky, Jamie Robinson, Daniela Mariosa, et al.
EBioMedicine (2024) Vol. 100, pp. 104991-104991
Open Access | Times Cited: 22
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 16
Targeting IL-23 for IBD: Rationale and Progress to Date
Sudheer K. Vuyyuru, Lisa M. Shackelton, Jurij Hanžel, et al.
Drugs (2023) Vol. 83, Iss. 10, pp. 873-891
Closed Access | Times Cited: 29
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
Yamin Shu, Jing Chen, Yiling Ding, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure
Mark Lebwohl, Joseph F. Merola, Katelyn Rowland, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 1, pp. 42-52
Open Access | Times Cited: 22
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
David Fudman, Ryan McConnell, Christina Ha, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 23, Iss. 3, pp. 454-468
Closed Access | Times Cited: 9
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Mario Valenti, Luciano Ibba, S. Di Giulio, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?
Zeev Elkoshi
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 841-852
Open Access | Times Cited: 6
The Role of IL-23 Inhibitors in Crohn’s Disease
Jacopo Fanizza, Ferdinando D’Amico, Francesca Lusetti, et al.
Journal of Clinical Medicine (2023) Vol. 13, Iss. 1, pp. 224-224
Open Access | Times Cited: 14
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years
April W. Armstrong, Mark Lebwohl, Richard B. Warren, et al.
JAMA Dermatology (2024)
Open Access | Times Cited: 5
Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
Fabrizio Calapai, Ilaria Ammendolia, Luigi Cardia, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1933-1933
Open Access | Times Cited: 12
Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes
Sara Horst, Raymond Cross
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 273-282
Open Access | Times Cited: 11
Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions
Joseph Clinton, Raymond K. Cross
Clinical and Experimental Gastroenterology (2023) Vol. Volume 16, pp. 249-276
Open Access | Times Cited: 11
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials
Andrew Blauvelt, April W. Armstrong, Joseph F. Merola, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 1, pp. 72-81
Open Access | Times Cited: 4
Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics
Xiaoyun Chen, Yutong Wu, Sujie Jia, et al.
Clinical Reviews in Allergy & Immunology (2024) Vol. 66, Iss. 3, pp. 274-293
Closed Access | Times Cited: 4
Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus
Tiago Torres, Nicolò Costantino Brembilla, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
Eficácia e segurança do risanquizumabe versus metotrexato em pacientes com psoríase em placas moderada a grave: Resultados do IMMbrace, estudo randomizado, duplo‐cego, de fase 3 com período de extensão aberto no Brasil
Tânia Ferreira Cestari, Cacilda da Silva Souza, Luna Azulay‐Abulafia, et al.
(2025)
Open Access
Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review
Daya Krishna Jha, Rinkal Kakadiya, Ananya Sharma, et al.
Autoimmunity Reviews (2025), pp. 103758-103758
Closed Access
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months
Diamant Thaçi, Mamitaro Ohtsuki, Julia‐Tatjana Maul, et al.
Dermatology and Therapy (2025)
Open Access
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
Joseph F. Merola, Laura K. Ferris, Jeffrey M. Sobell, et al.
Dermatology and Therapy (2025)
Open Access
IL-23 blockade in a patient with psoriasis and Toxoplasma gondii reactivation history: Case report and review
Jason Dagher, Julien Ringuet
SAGE Open Medical Case Reports (2025) Vol. 13
Open Access
Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment
Manfredo Bruni, Fabio Lobefaro, Cristina Pellegrini, et al.
Expert Opinion on Biological Therapy (2025), pp. 1-17
Closed Access
Risk factors for humanized IgG1 monoclonal antibody in the treatment of Crohn's disease: pharmacovigilance of the FDA adverse event reporting system (FAERS)
Jiangchuan Xie, Chun Tao, Linli Xie, et al.
Research Square (Research Square) (2025)
Closed Access
Page 1 - Next Page

Scroll to top